Subscribe
Business

News Summary: Amgen posts higher 2Q sales, profit

By The Associated Press
Published
Add Washington Examiner on Google

QUITE A QUARTER: Biotech giant Amgen surprised Wall Street with revenue of $4.48 billion, $400 million above expectations, and profit of $1.43 billion or $1.83 per share, 29 cents more than anticipated. Its stock jumped more than 5 percent.

PERFORMANCE KEYS: Most Amgen drugs had higher sales, and the company got a one-time $206 million gain from selling its share of an experimental lung cancer drug.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.